Factors Associated With Major Bleeding Events

Factors Associated With Major Bleeding Events

Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar ris...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2014-03, Vol.63 (9), p.891-900
Hauptverfasser: Goodman, Shaun G., MD, MSc, Wojdyla, Daniel M., MS, Piccini, Jonathan P., MD, White, Harvey D., MB, ChB, DSc, Paolini, John F., MD, PhD, Nessel, Christopher C., MD, Berkowitz, Scott D., MD, Mahaffey, Kenneth W., MD, Patel, Manesh R., MD, Sherwood, Matthew W., MD, Becker, Richard C., MD, Halperin, Jonathan L., MD, Hacke, Werner, MD, Singer, Daniel E., MD, Hankey, Graeme J., MD, Breithardt, Gunter, MD, Fox, Keith A.A., MB, ChB, Califf, Robert M., MD
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants
atrial fibrillation
Blood pressure
Cardiac arrhythmia
Cardiology
Cardiovascular
Confidence intervals
Diabetes
Drug dosages
Drug therapy
Embolisms
Heart failure
hemorrhage
Hepatitis
Hypertension
Internal Medicine
Nervous system
Older people
Risk factors
Stroke
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin. Methods The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model. Results The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category (
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2013.11.013